Lists of authors and their affiliations appear in the online version of the paper Breast cancer risk is influenced by rare coding variants in susceptibility genes, such as BRCA1, and many common, mostly non-coding variants. However, much of the genetic contribution to breast cancer risk remains unknown. Here we report the results of a genome-wide association study of breast cancer in 122,977 cases and 105,974 controls of European ancestry and 14,068 cases and 13,104 controls of East Asian ancestry 1 . We identified 65 new loci that are associated with overall breast cancer risk at P < 5 × 10 −8 . The majority of credible risk single-nucleotide polymorphisms in these loci fall in distal regulatory elements, and by integrating in silico data to predict target genes in breast cells at each locus, we demonstrate a strong overlap between candidate target genes and somatic driver genes in breast tumours. We also find that heritability of breast cancer due to all single-nucleotide polymorphisms in regulatory features was 2-5-fold enriched relative to the genomewide average, with strong enrichment for particular transcription factor binding sites. These results provide further insight into genetic susceptibility to breast cancer and will improve the use of genetic risk scores for individualized screening and prevention.
, none showed a significant difference in the estimated odds ratio for overall breast cancer risk between Europeans and Asians (P > 0.01; Supplementary Table 5 ). The correlation in effect sizes for all known loci between Europeans and Asians was 0.83, suggesting that the majority of known susceptibility loci are shared between these populations.
To search for additional susceptibility loci, we assessed all SNPs excluding those within 500 kb of a known susceptibility SNP ( Fig. 1) . This identified 5,969 variants in 65 regions that were associated with overall breast cancer risk at P < 5 × 10 −8 (Supplementary Tables 6-8). For two loci (lead SNPs rs58847541 and rs12628403), there was evidence of a second association signal after adjustment for the primary signal (rs13279803: conditional P = 1.6 × 10 −10 ; rs373038216: P = 2.9 × 10; Supplementary Table 9 ). Of the 65 new loci, 21 showed a differential association based on oestrogen receptor (ER) status (P < 0.05), with all but two SNPs (rs6725517 and rs6569648) more strongly associated with ER-positive disease (Supplementary Tables 10, 11). Forty-four loci showed evidence of association with ER-negative breast cancer (P < 0.05). Of the 51 novel loci that were polymorphic in Asians, nine were associated at P < 0.05 and only two showed a difference in the estimated odds ratio between Europeans and Asians (P < 0.01; Supplementary Table 12 ).
To define a set of credible risk variants (CRVs) at the new loci, we first selected variants with P values within two orders of magnitude of the most significant SNPs in each region. Across the 65 novel regions, we identified 2,221 CRVs ( Supplementary Table 13 ), while the 77 previously identified loci contained 2,232 CRVs (Methods and Supplementary Table 14 ). We examined these CRVs for evidence of enrichment of 67 genomic features, including histone markers and transcription factor binding sites in three breast cancer cell lines (Methods, Extended Data Fig. 1 and Supplementary Tables 15, 16 ). Thirteen features were significant predictors of CRVs at P < 10 −4 ; the strongest were DNase I hypersensitivity sites in CTCF-silenced MCF7 cells (odds ratio = 2.38, P = 4.6 × 10 −14 ). Strong associations were also observed at binding sites for FOXA1, ESR1, GATA3, E2F1 and TCF7L2. In addition, 7 of the 65 novel loci included only a single CRV ( Supplementary Table 6 ), of which two were non-synonymous. SNP rs16991615 is a missense variant (p.Glu341Lys) in MCM8, which is involved in genome replication and associated with age at natural menopause and impaired DNA repair 6 . SNP rs35383942 is a missense variant (p.Arg28Gln) in PHLDA3, encoding a p53-regulated repressor of AKT 7 .
We annotated each CRV with publicly available genomic data from breast cells in order to highlight potentially functional variants, predict target genes and prioritize future experimental validation ( Supplementary Tables 7, 13 with UCSC (University of California Santa Cruz) browser links). We developed a heuristic scoring system based on breast-specific genomic data (integrated expression quantitative trait and in silico prediction of GWAS targets (INQUISIT)) to rank the target genes at each locus ( Supplementary Table 17 ). Target genes were predicted by combining risk SNP data with multiple sources of genomic information, including chromatin interactions (chromatin interaction analysis by paired-end tag sequencing (ChIA-PET) and genome-wide chromosome conformation capture (Hi-C)), computational enhancer-promoter correlations (PreSTIGE (ref. 8), IM-PET (ref. 9), FANTOM5 (ref. 10) and super-enhancers), results for breast tissue-specific expression quantitative trait loci (eQTLs), transcription factor binding (ENCODE (Encyclopedia of DNA Elements) chromatin immunoprecipitation followed by sequencing (ChIP-seq)), gene expression (ENCODE RNA sequencing (RNA-seq)) and topologically associated domain boundaries (Methods and Supplementary Tables  18-20) . Target gene predictions could be made for 58 out of 65 new and 70 out of 77 previously identified loci. Among 689 protein-coding genes predicted by INQUISIT, we found strong enrichment for esta blished breast cancer drivers identified through tumour sequencing (20 out of 147 genes, P < 10 −6 ) 11-14 , which increased with increasing INQUISIT score (P = 1.8 × 10 −6 ). We compared INQUISIT with two alternative methods. Firstly, an alternative, published method (Data-driven Expression-Prioritized Integration for Complex Traits (DEPICT), which predicts targets based on shared gene functions between potential targets at other associated loci) 15 showed a weaker enrichment of breast cancer driver genes (P = 0.06 after adjusting for the nearest gene, P = 0.74 after adjusting for INQUISIT score). Secondly, after assigning the association signal to the nearest gene, only a weak enrichment of driver genes after adjusting for the INQUISIT score was found (P = 0.01; Extended Data Table 1 and Supplementary Table 21 ). Notably, most of the 689 putative target genes have no reported involvement in breast tumorigenesis and some may represent additional genes that influence the susceptibility to breast cancer. However, functional assays will be required to confirm whether any of these candidate genes is causally implicated in breast cancer susceptibility.
Having used INQUISIT to predict target genes, we performed pathway gene set enrichment analysis, the results of which are visually summarized as enrichment maps 16 (Extended Data Fig. 2 and Supplementary Tables 22, 23) . Several growth or development related pathways were enriched, notably the fibroblast growth factor, platelet-derived growth factor and Wnt signalling pathways [17] [18] [19] . Other cancer-related themes included ERK1/2 cascade, immune-response pathways, including interferon signalling, and cell-cycle pathways. Pathways that were not found in earlier breast cancer GWAS include nitric-oxide biosynthesis, AP-1 transcription factor and NF-κ B ( Supplementary Table 24 ).
To explore more globally the genomic features that contribute to breast cancer risk, we estimated the proportion of genome-wide SNP heritability attributable to 53 publicly available annotations 20 . We observed the largest enrichment in heritability (5.2-fold, P = 8.5 × 10 −5 ) of transcription factor binding sites, followed by a fourfold (P = 0.0006) enrichment of histone marker H3K4me3 (marking promoters). By contrast, we observed a significant depletion (0.27, P = 0.0007) in repressed regions ( Supplementary Table 25 ). We conducted cell-typespecific enrichment analysis for four histone markers and observed significant enrichments in several tissue types (Extended Data Figs 3-7  and Supplementary Table 26 , 27), including a 6.7-fold enrichment of H3K4me1 in breast myoepithelial tissue (P = 7.9 × 10 −5 ). We compared the cell-type-specific enrichments for all, ER-positive and ER-negative breast cancers to the enrichments for 16 other complex traits (Extended Data Figs 3-7). Breast cancer showed enrichment in adipose and epithelial cell types (including breast epithelial cells). By contrast, psychiatric diseases showed enrichment specific to cell types of the central nervous system and autoimmune disorders showed enrichment in immune cells.
We selected four loci for further evaluation to represent those that are predicted to act through proximal regulation (1p36 and 11p15) and distal regulation (1p34 and 7q22), because they had a relatively small number of CRVs. Firstly, the only CRV at 1p36, rs2992756 (P = 1.6 × 10 −15 ), is located 84 bp from the transcription start site of KLHDC7A. Secondly, of the 19 CRVs at 11p15 (smallest P = 1.4 × 10 −12 ), five were located in the proximal promoter of PIDD1, which is implicated in DNA-damage-induced apoptosis and tumorigenesis 21 . INQUISIT predicted KLHDC7A and PIDD1 to be target genes and these genes had the highest score for the likelihood of promoter regulation ( Supplementary Table 19 ). Using reporter assays, we showed that the KLHDC7A promoter construct containing the risk T-allele of rs2992756 has significantly lower activity than the reference construct, while the PIDD1 promoter construct containing the risk haplotype significantly increased PIDD1 promoter activity (Extended Data Fig. 8 ).
Thirdly, the 1p34 locus included four CRVs (smallest P = 9.1 × 10 −9 ) that are within two putative regulatory elements (PREs) and are predicted by INQUISIT to regulate CITED4 (Extended Data Fig. 8 ). CITED4 encodes a transcriptional coactivator that interacts with CBP, p300 and TFAP2 and can inhibit hypoxia-activated transcription in cancer cells 22 . Chromatin conformation capture assays confirmed that the PREs physically interacted with the CITED4 promoter (Extended Data Fig. 8 ). Subsequent reporter assays showed that the PRE1 reference construct reduced CITED4 promoter activity, whereas the risk T-allele of SNP rs4233486 located in PRE1 negates this effect.
Finally, the 7q22 risk locus contained six CRVs (smallest P = 5.1 × 10 −12 ) that were found to be in several PREs spanning around 40 kb of intron 1 of CUX1. Chromatin interactions were identified between PRE1 (containing SNP rs6979850) and the promoters of CUX1 and RASA4 and between PRE2 (containing SNP rs71559437) and the promoters of RASA4 and PRKRIP1 (Extended Data Fig. 9 ). Allele-specific chromatin conformation capture assays in hetero zygous MBA-MB-231 cells showed that the risk haplotype was associated with chromatin looping, suggesting that the protective allele abrogates looping between the PREs and target genes (Extended Data Fig. 9 ). These results identify two mechanisms by which CRVs may affect target gene expression: through transactivation of a specific promoter and by affecting chromatin looping between regulatory elements and their target genes. These data provide in vitro evidence of target identification Letter reSeArCH and regulation; however further studies that include genome editing, oncogenic assays and/or animal models will be required to fully elucidate disease-related gene function.
We estimate that the newly identified susceptibility loci explain around 4% of the twofold familial relative risk of breast cancer and that in total, common susceptibility variants identified through GWAS explain 18% of the familial relative risk. Furthermore, we estimate that variants that can be reliably imputed using the OncoArray explain around 41% of the familial relative risk, assuming a log-additive model (see Methods). Therefore, the identified susceptibility SNPs account for around 44% (18% out of 41%) of the familial relative risk that can be explained by all imputable SNPs. The identified SNPs will be incorporated into risk prediction models, which can be used to improve the identification of women that are at high or low risk of breast cancer: for example, using a polygenic risk score based on the variants that have been identified to date, women in the highest 1% of the distribution have a 3.5-fold greater risk of breast cancer than the population average. Such risk prediction can inform targeted early detection and prevention.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. Supplementary Information is available in the online version of the paper.
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Details of the studies and genotype calling and quality control for the iCOGS and eleven other GWAS are described elsewhere 2,23 . Seventy-eight studies participated in the breast cancer component of the OncoArray, of which 67 studies contribu ted European ancestry data and 12 contributed Asian ancestry data (one study, NBCS, was excluded as there were no controls from Norway) ( Supplementary Table 1 ). The majority of studies were population-based case-control studies, or casecontrol studies nested within population-based cohorts, but a subset of studies oversampled cases with a family history of the disease. All studies provided core data on disease status and age at diagnosis or observation, and the majority provided additional data on clinico-pathological and lifestyle factors, which have been curated and incorporated into the BCAC database (version 6). All participating studies were approved by their appropriate ethics review board and all subjects provided informed consent. OncoArray SNP selection. Approximately 50% of the SNPs for the OncoArray were selected as a 'GWAS backbone' (Illumina HumanCore), which aimed to provide high coverage for the majority of common variants through imputation. The remaining SNPs were selected from lists supplied by each of six disease-based consortia, together with a seventh list of SNPs of interest to multiple diseasefocused groups. Approximately 72 thousand SNPs were selected specifically for their relevance to breast cancer. These included: (a) SNPs showing evidence of association from previous genotype data, based on a combined analysis of eleven existing GWAS together with the data from the iCOGS experiment; (b) SNPs showing evidence of association with ER-negative disease (through a combined analysis with the CIMBA consortium), triple-negative disease, breast cancer diagnosed before the age of 40 years, high-grade disease, node-positive disease or ductal carcinoma in situ; (c) SNPs potentially associated with breast cancer survival; (d) SNPs selected for fine-mapping of 55 regions showing evidence of breast cancer association at genome-wide significance; (e) rare variants showing evidence of association through exome sequencing in multiple case families, whole-genome sequencing in high-risk cases (DRIVE) or analysis of the ExomeChip (BCAC); (f) specific follow-up of regions of interest from breast cancer GWAS in Asian, Latina and African/African-American women; (g) SNPs associated with breast density, selected from GWAS conducted by the MODE consortium; (h) breast tissue-specific eQTLs; (i) lists of functional candidates from > 30 groups. Lists were merged with lists from the other consortia as described elsewhere 1 . OncoArray calling and quality control. Of the 568,712 variants selected for genotyping, 533,631 were successfully manufactured on the array (including 778 duplicate probes). Genotyping for the breast cancer component of the OncoArray, which included 152,492 samples, was conducted at six sites. Details of the genotyping calling for the OncoArray are described in more detail elsewhere 1 . In brief, we developed a single calling pipeline that was applied to more than 500,000 samples. An initial cluster file was generated using data from 56,284 samples, selected to cover all the major genotyping centres and ethnicities, using the Gentrain2 algorithm. Variants that were likely to have problematic clusters were selected for manual inspection using the following criteria: call rate below 99%, variants with minor allele frequency (MAF) < 0.001, poor Illumina intensity and clustering metrics, or deviation from the expected frequency as observed in the 1000 Genomes Project. This resulted in manual adjustment of the cluster file for 3,964 variants, and the exclusion of 16,526 variants. The final cluster file was then applied to the full dataset.
We excluded probable duplicates and close relatives within each study, and probable duplicates across studies. We excluded samples with a call rate < 95% or samples with extreme heterozygosity (4.89 s.d. from the mean for the ethnicity). Ancestry was computed using a principal component analysis, applied to the full OncoArray dataset, using 2,318 informative markers on a subset of around 47,000 samples. The analysis presented here was restricted to women of European ancestry, defined as individuals with an estimated proportion of European ancestry > 0.8, and women of East Asian ancestry (estimated proportion of Asian ancestry > 0.4), with reference to the HapMap (v.2) populations, based on the first two principal components. After quality control exclusions and removing overlaps with the previous iCOGS and GWAS genotyping used in the analysis, the final dataset comprized data from 61,282 cases and 45,494 of European ancestry and 7,799 cases and 6,480 controls of Asian ancestry.
We excluded SNPs with a call rate < 95% in any consortium, SNPs not in Hardy-Weinberg equilibrium (P < 10 −7 in controls or P < 10 −12 in cases) and SNPs with concordance < 98% among 5,280 duplicate sample pairs. For the imputation, we additionally excluded SNPs with a MAF < 1% and a call rate < 98% in any consortium, SNPs that could not be linked to the 1000 Genomes Project reference or differed significantly in frequency from the 1000 Genomes Project dataset (using
, where p 0 and p 1 are the MAFs in the 1000
Genomes Project and OncoArray European datasets, respectively). A further 1,128
SNPs for which the cluster plots were judged, on visual inspection, to be too poor to call genotypes reliably were excluded. Of the 533,631 SNPs that were manufactured on the array, 494,763 SNPs passed the initial quality control and 469,364 SNPs were used in the imputation. Genotype imputation. All samples were imputed using the October 2014 (version 3) release of the 1000 Genomes Project dataset as the reference panel and the number of sampled haplotypes per individual (n hap ) = 800. The iCOGS, OncoArray and nine of the GWAS datasets were imputed using a two-stage imputation approach, using SHAPEIT2 for phasing and IMPUTE version 2 for imputation 24, 25 . The imputation was performed in 5-Mb non-overlapping intervals. The subjects were split into subsets of approximately 10,000 samples; where possible subjects from the same study were included in the same subset. The BPC3 and EBCG studies were imputed separately using MACH and Minimac 26, 27 . In total, 99.6% of SNPs with frequency > 1% were imputable with r 2 > 0.3 in the OncoArray dataset and 99.1% in the iCOGS dataset. We generated estimated genotypes for all SNPs that were polymorphic (MAF > 0.1%) in either European or Asian samples (around 21 million SNPs). For the current analysis, however, we restricted our analysis to SNPs with MAF > 0.5% in the European OncoArray dataset (11.8 million SNPs). One-step imputation (without pre-phasing) was performed on the iCOGS and OncoArray datasets, as a quality control step for those associated loci where the imputation quality score was < 0.9. Imputation quality for the lead variants, as assessed by the IMPUTE version 2 quality score in the OncoArray dataset, was > 0.80 for all but one locus (rs72749841, quality score = 0.65; see Supplementary  Table 28 ). Principal components analysis. To adjust for potential (intra-continental) population stratification in the OncoArray dataset, principal components analysis was performed using data from 33,661 uncorrelated SNPs (which included 2,318 SNPs specifically selected on informativeness for determining continental ancestry) with a MAF of at least 0.05 and maximum correlation of 0.1 in the OncoArray dataset, using purpose-written software (http://ccge.medschl.cam.ac.uk/software/pccalc). For the main analyses, we used the first ten principal components, as additional components did not further reduce inflation in the test statistics. We used nine principal components for the iCOGS and up to ten principal components for the other GWAS, where this was found to reduce inflation. Statistical analyses. No statistical methods were used to predetermine sample size. Genotyping was conducted without knowledge of the disease phenotypes. Per-allele odds ratios and standard errors were generated for the OncoArray, iCOGS and each GWAS, adjusting for principal components using logistic regression. The OncoArray and iCOGS analyses were additionally adjusted for country and study, respectively. For the OncoArray analysis, we adjusted for country and 10 principal components. Adjustment for country rather than study was used to improve power because some studies had few or no controls. We evaluated the adequacy of this approach by comparing the inflation in the test statistic with that obtained in corresponding analysis in which we adjusted for study-the inflation was very similar (λ = 1.15 versus 1.17, based on the backbone SNPs, equivalent to λ 1,000 = 1.003, for a study of 1,000 cases and 1,000 controls, in both cases). As an additional sensitivity analysis, we computed the effect sizes for the 65 novel loci adjusting for study-the effect sizes were essentially identical to those presented. Estimates were derived using ProbAbel for the BPC3 and EBCG studies 28 , SNPTEST for the remaining GWAS and purpose-written software for the iCOGS and OncoArray datasets. Odds ratio estimates and standard errors were combined in a fixed-effects, inverse-variance meta-analysis using METAL 29 , adjusting the GWAS (but not iCOGS or OncoArray) results for genomic control as described previously 2 . For the GWAS, results were included in the analysis for all SNPs with MAF ≥ 0.01 and imputation r 2 ≥ 0.3. For iCOGS and OncoArray, we included all SNPs with r 2 ≥ 0.3 and MAF ≥ 0.005 (11.8 million SNPs in total). We used the tests that were based on the meta-analysis over all stages as the primary tests of association, because this type of analysis has been shown to be more powerful than tests that were based on a test-replication approach 30 . Eight sets of variants were associated with breast cancer at P < 5 × 10 −8 , but were close to previous susceptibility regions, and these became non-significant after adjustment for the previously identified lead variant. Two SNPs on 22q13.2, rs141447235 and rs73161324, were both associated with overall breast cancer risk but, despite lying > 500 kb apart, were strongly correlated with each other (r 2 = 0.50) and were therefore considered a single novel signal. For SNPs showing evidence of association, we additionally computed genotype-specific odds ratios for the iCOGS and OncoArray dataset, and perallele odds ratios for ER-negative and ER-positive disease. Departures from a logadditive model were evaluated using a one degree of freedom likelihood ratio test, comparing the log-additive model (genotypes parameterized as the number of rare alleles carried) with the general model estimating odds ratios for each genotype. The genotype-specific risks for all variants were consistent with a log-additive model (P > 0.01; Supplementary Table 29 ). Tests for differences in the odds ratio by Letter reSeArCH ER-status were derived using case-only analyses, in which estimates were derived by logistic regression separately in the iCOGS and OncoArray datasets, adjusted as before, and then combined in a fixed-effects meta-analysis. These analyses were performed in R 31 .
We assessed heterogeneity in the odds ratio estimates among studies within each of the OncoArray, iCOGS and GWAS components, and between the (combined) estimates for the three components, using both the I 2 statistic and the P value for Cochran's Q statistic ( Supplementary Table 28 ). There was no evidence of heterogeneity among studies in the odds ratios for any of the loci in the OncoArray, but three loci showed some evidence of heterogeneity in the odds ratios among the GWAS, iCOGS and OncoArray datasets.
To determine whether there were multiple independent signals in a given region, we performed multiple logistic regression analysis using SNPs within 500 kb of each lead SNP, adjusting for the lead SNP. We used the genotypes derived by onestep imputation, performed the analyses separately in the iCOGS and Oncoarray datasets and combined the results (adjusted effect sizes and standard errors) using a fixed-effects meta-analysis. For one of the two loci for which there was an additional signal significant at P < 5 × 10 −8 , the lead SNP from the one-step imputation differed from the lead SNP in the overall analysis, but was strongly correlated with it (Supplementary Table 9 ). Definition of known hits. We attempted to identify all associations previously reported from genome-wide or candidate analysis at a significance level P < 5 × 10 −8 for all breast cancer types, ER-negative or ER-positive breast cancer, in BRCA1 or BRCA2 carriers, or in meta-analyses of these categories. Where multiple studies reported associations in the same region, we used the first reported association unless later studies identified a variant that was clearly more strongly associated. We only included one SNP per 500 kb interval, unless joint analysis provided clear evidence (P < 5 × 10 −8 ) of more than one independent signal. For the analysis of CRVs, we restricted our analysis to regions in which the most significant signal had a P value < 10 −7 in Europeans (77 regions). To avoid complications with defining CRVs for secondary signals, we considered only the primary signal and defined CRVs as those for which the P value was within two orders of magnitude of the most significant P value. In silico analysis of CRVs. We combined multiple sources of in silico functional annotation from public databases to help to identify potential functional SNPs and target genes. To investigate functional elements enriched across the region encompassing the strongest CRVs, we analysed data of chromatin biofeatures from the Encyclopedia of DNA Elements (ENCODE) Project 32 , Roadmap Epigenomics Projects 33 and other data obtained through the National Center for Biotechnology Information (NCBI) gene expression omnibus (GEO) namely: chromatin state segmentation by hidden Markov Models (chromHMM), DNase I hypersensitive and histone modifications of epigenetic markers H3K4, H3K9 and H3K27 in human mammary epithelial (HMEC) and myoepithelial cells, T47D and MCF7 breast cancer cells and transcription factor ChIP-seq in a range of breast cell lines ( Supplementary Table 13 ). Association of genomic features with CRVs. We first defined credible candidate variants as those located within 500 kb of the most significant SNP in each region, and with P values within two orders of magnitude of the most significant SNPs. This is approximately equivalent to flagging variants whose posterior probability of causality is within two orders of magnitude of the value of the most significant SNP 34, 35 . We then selected 800 random 1-Mb control regions that were at least 1 Mb from each other and from the intervals defined by the associated SNPs. The association with each feature was then evaluated using logistic regression, with being a CRV as the outcome, and adjusting for the dependence due to linkage disequilibrium using robust variance estimation, clustering on region, using the R package multiwayvcov. eQTL analyses. eQTL analyses were performed using data from The Cancer Genome Atlas (TCGA) and Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) projects 12, 36 . The TCGA eQTL analysis was based on 458 breast tumours that had matched gene expression, copy number and methylation profiles together with the corresponding germline genotypes available. All 458 individuals were of European ancestry as ascertained using the genotype data and the Local Ancestry in adMixed Populations (LAMP) software package (LAMP estimate cut-off > 95% European) 37 . Germline genotypes were imputed into the 1000 Genomes Project reference panel (October 2014 release) using IMPUTE version 2 (refs 26, 38) . Gene expression had been measured on the Illumina HiSeq 2000 RNA-Seq platform (gene-level RSEM normalized counts 39 ), copy-number estimates were derived from the Affymetrix SNP 6.0 (somatic copy-number alteration minus germline copy-number variation called using the GISTIC2 algorithm 40 ), and methylation beta values measured on the Illumina Infinium HumanMethylation450. eQTL analysis focused on all variants within 500 kb of the most significantly associated risk SNP in 142 genomic regions (each 2-Mb wide) containing at least one previously identified or new overall breast cancer risk locus confirmed at genome-wide significance in the current meta-analysis. Each variant was evaluated for its association with the expression of every gene within 2 Mb that had been profiled for each of the three data types. The effects of tumour copy number and methylation on gene expression were first regressed out using a method described previously 41 . eQTL analysis was performed by linear regression, with residual gene expression as outcome, germline SNP genotype dosage as the covariate of interest and ESR1 expression and age as additional covariates, using the R package Matrix eQTL 42 .
The METABRIC eQTL analysis was based on 138 normal breast tissue samples resected from breast cancer patients of European ancestry. Germline genotyping for the METABRIC study was also done on the Affymetrix SNP 6.0 array, and gene expression in the METABRIC study was measured using the Illumina HT12 microarray platform (probe-level estimates). No adjustment was implemented for somatic copy number and methylation status since we were evaluating eQTLs in normal breast tissue. All other steps were identical to the TCGA eQTL analysis described above. INQUISIT. We developed a computational pipeline, the integrated expression quantitative trait and in silico prediction of GWAS targets (INQUISIT), to interrogate publically available data for the prioritization of candidate target genes. Data used for INQUISIT. Chromatin interaction data from ENCODE ChIA-PET analysis in MCF-7 cells for RNApolII, ERα and CTCF factors were downloaded using the UCSC Table Browser 43 . Hi-C data derived from HMECs were obtained from ref. 44, using 'interaction loops' as defined in ref. 44 . Data were reformatted to facilitate intersection of query SNPs using BEDTools 'intersect' 45 . For all interactions, termini were intersected with promoters using GENCODE version 19 (ref. 46 ) basic gene annotations, for which we defined promoters as − 1.0 kb to + 0.1 kb surrounding a transcription start site.
Enhancer-target gene predictions of several computational algorithms were collected. Each of these datasets assigned genes to enhancers. We used all MCF-7 and HMEC enhancer predictions (low and high stringency) made by PreSTIGE 8 , IM-PET enhancer-gene predictions in MCF-7, HMEC and HCC1954 cell lines 9 . Enhancer-transcription start site (E-TSS) links were identified from the FANTOM5 Consortium 10 , and enhancers detected in mammary epithelial cells were intersected with E-TSS links. We also collected typical and super-enhancers in MCF-7, HMEC and HCC1954 cells defined in ref. 47 .
ChIP-seq peak data for transcription factors ESR1, FOXA1, GATA3, TCF7L2 and E2F1 from MCF-7, T47D and MCF-10A cells were downloaded in narrowPeak format from ENCODE. ChIP-seq peak data for H3K4me3 and H3K9ac (characteristic of promoters) histone modification for all breast cells were obtained from ENCODE and Roadmap Epigenomics Project. ChromHMM data for breast cell samples (HMEC and myoepithelial: E027, E028 and E119) were downloaded from Roadmap Epigenomics. eQTL analyses were conducted as described above. For the interpretation of the eQTL results for INQUISIT (and in general), we focused on the overlap between the CRVs (risk signal) and the top eQTL variants for a given gene (eQTL signal). If the eQTL P value for a CRV was the same as, or within 1/100th of the eQTL P value of the SNP most significantly associated with expression of a particular gene, that gene and the corresponding CRV were assigned a point for being an eQTL in INQUISIT.
Topologically associated domain (TAD) boundaries were derived from Hi-C data 44 . Genomic intervals corresponding to 'contact domains' from eight human cell types were merged using BEDTools 'merge' resulting in annotation of regions that were most likely to encompass TAD units. Inter-TAD boundaries were identified using BEDTools 'complement' .
Gene level RNA-seq expression data generated under multiple experimental conditions in MCF-7 and normal mammary epithelial cells were downloaded from ENCODE. The FPKM (fragments per kilobase of exon per million fragments mapped) values for each gene were extracted using the metagene R package 48 and averaged across all experiments to give an approximation of expression in breast cells. Accession numbers of previously published data are given in Supplementary  Table 30 . Inquisit pipeline. Candidate target genes were evaluated by assessing the potential impact of each CRV on regulatory or coding features. Scores categorized by (a) distal gene regulation, (b) proximal gene regulation or (c) impact on protein coding were calculated using the following criteria (see Supplementary Table 17 ).
Genomic annotation data for target gene predictions (chromatin interaction and computational enhancer-promoter assignment), ChIP-seq, histone modification and chromHMM were curated into a BED-formatted database. We intersected the chromosomal positions of CRVs with each category of genomic annotation data using BEDTools 'intersect' (minimum 1-bp overlap), resulting in annotation of SNP-gene pairs with presence or absence of multiple classes of genomic data. Each gene was scored using a custom R script on the basis of the following criteria. (a) For distally regulated genes, a candidate gene was given two points if a CRV Letter reSeArCH fell in an element that revealed long-range ChIA-PET or Hi-C interactions with the promoter of that gene. One point was added to a gene's score in the case of enhancers predicted by computational methods to target that gene (in addition to experimental interactions if also observed). If the distal elements containing the SNPs also overlapped enriched cistromic transcription factor (ESR1, FOXA1, GATA3, TCF7L2, E2F1) ChIP-seq peaks, an additional point was given when an overlap between a SNP, enhancer and ChIP-seq peak occurred, and two points were added when there were multiple transcription factor binding sites that were overlapping with SNPs in distinct interactions or enhancers (see Supplementary  Table 17 for details). One point was given to significant eSNP-eGENE pairs. Predicted distal target genes that were among the list of breast cancer driver genes were up-weighted with a further point (except for the analysis of driver gene enrichment). Information regarding TAD boundaries was used to downweight genes: genes that were separated from CRVs by a TAD boundary were down-weighted by multiplying their scores by 0.05. Scores for genes exhibiting no expression in MCF7 or HMEC (mean FPKM = 0) were multiplied by 0.1. This resulted in scores for each candidate target gene ranging from 0 to 8. (b) Variants were treated as potentially affecting proximal promoter regulation if they resided between − 1.0 and + 0.1 kb surrounding a transcription start site. Additional points were awarded to genes when variants overlapped promoter H3K4me3 or H3K9ac histone-modification peaks, intersected with ESR1, FOXA1, GATA3, TCF7L2 or E2F1 transcription factor binding sites, were significant eSNP-eGENE pairs, and if the gene was annotated as a breast cancer driver gene. Gene scores were down-weighted (by a factor of 0.1) if they lacked expression in MCF-7 or HMEC samples. Resultant scores ranged from 0 to 5. (c) Intragenic variants were evaluated for their potential to impact protein function using a range of in silico prediction tools (CADD 49 55 and SIFT 56 for missense variants; Human Splicing Finder 57 and MaxEntScan 58 for splice variants). We scored genes with missense and nonsense variants predicted to be functionally deleterious, and points for genes containing variants predicted to alter splicing. Genes could therefore carry SNPs that affect coding and splicing and receive increased scores. Additional points were given to genes that were breast cancer driver genes. We multiplied scores by 0.1 when genes showed a lack of expression in breast cells. Possible coding scores ranged from 0 to 4. Enrichment of somatic breast cancer driver genes in INQUISIT target gene predictions. We listed 147 unique protein-coding driver genes for breast cancer identified from four recent tumour genome-and exome-sequencing studies [11] [12] [13] [14] (considering ZNF703 and FGFR1 as independent genes; Supplementary Table 31 ). First, we examined overlap between this list of 147 genes and the total set of unique target genes predicted by INQUISIT (n = 689) by one or more of the three regulatory mechanisms (distal, promoter and coding). The significance of this overlap was assessed by randomly drawing (without replacement) 689 genes from the set of all protein-coding genes (GENCODE release 19, n = 20,243) one million times and calculating the probability of observing the same (or stronger) overlap with the list of 147 drivers. Second, we hypothesized that this enrichment would be stronger with progressively higher INQUISIT scores. We categorized all 20,243 protein-coding genes into four levels based on their INQUISIT scores (level 1: coding score 2, promoter score 3-4, distal score > 4; level 2: coding score 1, promoter score 1-2, distal score 1-4; level 3: any score > 0 but < 1; level 4: score 0 that is, not a predicted target). The gene nearest to a risk locus is frequently assigned as a candidate target gene in GWAS in the absence of additional functional analysis 59 . We observed that 7 of the 147 drivers were among the genes nearest to a previously or newly identified breast cancer risk locus. Therefore, we used logistic regression, including data for all target genes predicted by INQUISIT, with driver status as outcome, and evaluated INQUISIT score level and nearest gene status as potential predictors of driver status ( Supplementary Table 21 ).
Lead SNPs at 142 breast cancer risk-associated loci were used as input into DEPICT, which was then run using the default settings 15 . We examined the relative performance of INQUISIT and DEPICT in predicting driver gene status using logistic regression models as above ( Supplementary Table 21 ), adding DEPICT prediction as a covariate. Chromatin conformation capture (3C). MCF7 (ATCC HTB22) and MDA-MB-231 (ATCC HTB26) breast cancer cell lines were grown in RPMI medium with 10% FCS and antibiotics. Bre-80 normal breast epithelial cells (provided as a gift from R. Reddel) were grown in DMEM/F12 medium with 5% horse serum, 10 μ g ml −1 insulin, 0.5 μ g ml −1 hydrocortisone, 20 ng ml −1 epidermal growth factor, 100 ng ml −1 cholera toxin and antibiotics. Cell lines were maintained under standard conditions, routinely tested for Mycoplasma and short tandem repeat profiled to confirm cell line identity. 3C libraries were generated using EcoRI as described previously 60 . 3C interactions were quantified by real-time PCR (qPCR) using primers designed within restriction fragments ( Supplementary Table 32 ). qPCR was performed on a RotorGene 6000 using MyTaq HS DNA polymerase (Bioline) with the addition of 5 mM of Syto9, annealing temperature of 66 °C and extension of 30 s. 3C analyses were performed in three independent 3C libraries from each cell line with each experiment quantified in duplicate. BAC clones covering each region were used to create artificial libraries of ligation products in order to normalize for PCR efficiency. Data were normalized to the signal from the BAC clone library and, between cell lines, by reference to a region within GAPDH. All qPCR products were electrophoresed on 2% agarose gels, gel purified and sequenced to verify the 3C product. Plasmid construction and reporter assays. Promoter-driven luciferase reporter constructs were generated by insertion of PCR amplified fragments or synthesized gBlocks (Integrated DNA Technologies), containing the KLHDC7A, PIDD1 or CITED4 promoters, into the KpnI/HindIII sites of pGL3-Basic. For the 1p34 locus, a 1,169-bp putative regulatory element (PRE1) or 951-bp PRE2 were synthesized as gBlocks and cloned into the BamHI/SalI sites of the CITED4-promoter construct. The minor alleles of SNPs were introduced into promoter or PRE sequences by overlap extension PCR or gBlocks. Sequencing of all constructs confirmed variant incorporation (AGRF). MCF7 or Bre-80 cells were transfected with equimolar amounts of luciferase reporter plasmids and 50 ng of pRLTK transfection control plasmid with Lipofectamine 2000. The total amount of transfected DNA was kept constant at 600 ng for each construct by the addition of pUC19 as a carrier plasmid. Luciferase activity was measured 24 h after transfection by the Dual-Glo Luciferase Assay System. To correct for any differences in transfection efficiency or cell-lysate preparation, Firefly luciferase activity was normalized to Renilla luciferase, and the activity of each construct was measured relative to the reference promoter constructs, which had a defined activity of 1. Statistical significance was tested by log transforming the data and performing a two-way ANOVA, followed by Dunnett's multiple comparisons test in GraphPad Prism. Global genomic enrichment analyses. We performed stratified LD score regression analyses 20 for all breast cancers and for breast cancers stratified by ER status using the summary statistics based on the meta-analyses of the OncoArray, GWAS and iCOGS datasets. We restricted analysis to all SNPs present on the HapMap version 3 dataset that had a MAF > 1% and an imputation quality score r 2 > 0.3 in the OncoArray data. LD scores were calculated using the 1000 Genomes Project Phase 3 EUR reference panel.
We first created a 'full baseline model' as previously described that included 24 non-cell-type-specific, publicly available annotations as well as 24 additional annotations that included a 500-bp window around each of the 24 main annotations 20 . Additionally, we included 100-bp windows around ChIP-seq peaks and one annotation containing all SNPs, leading to a total of 53 overlapping annotations.
We subsequently performed analyses using cell-type-specific annotations for four histone markers, H3K4me1, H3K4me3, H3K9ac and H3K27ac, across 27-81 cell types depending on the histone marker 20 . Each cell-type-specific annotation corresponded to a histone marker in a single cell type, and there were 220 annotations in total. We augmented the baseline model by adding these annotations individually, creating 220 separate models, each with 54 annotations (53 + 1). This procedure controls for the overlap with the 53 functional categories in the full baseline model but not with the 219 other cell-type-specific annotations.
We further tested the differences in functional enrichment between ER-positive and ER-negative subsets through a Wald test, using the regression coefficients and standard errors for the two subsets based on the models described above.
Contribution of identified variants to the familial relative risk of breast cancer.
We estimated the proportion of the familial risk of breast cancer due to the identified variants, under a log-additive model, using the formula: ∑
where p i is the MAF for variant i, β i is the log(odds ratio) estimate for variant i, τ i is the standard error of β i and λ = 2 is the assumed overall familial relative risk (FRR 67 . For GO, terms inferred from electronic annotation were excluded from our analyses. The same pathway may be defined in two or more databases with potentially different sets of genes. All versions of such 'duplicate' pathways were included. To provide more biologically meaningful results and reduce false positives, only pathways that contained between 10 and 200 genes were used. Pathway size was determined by the total number of genes in the pathway that could also be mapped to the genes included in the GWAS dataset (actual pathway size may be larger).
SNPs were assigned to genes using the INQUISIT target prediction method described above for all SNPs with P < 5 × 10 −2 (around 1.25 million associations). This cut-off was chosen based on a threshold analysis that showed that 19 of the 20 pathway themes found using all SNP associations (around 16 million) and a simple distance-based SNP-to-gene mapping method could be recovered using this smaller subset of associations. More stringent cut-offs resulted in fewer themes being covered (for example, three themes found using SNPs with P < 5 × 10 −6 or around 33 thousand SNP associations). Gene significance was calculated by assigning the statistic of the most significant SNP among all SNPs assigned to a gene 68, 69 . Because histone genes contained a high number of mapped SNPs, we selected representative SNP associations to avoid pathway enrichments based solely on the increased number of SNPs at these loci (that is, chr6:27657944 for HIST1; chr1:149219841 for HIST2; chr1:228517406 for HIST3; chr12:14871747 for HIST4).
The gene set enrichment analysis algorithm as implemented in the GenGen package 69 was used to perform pathway analysis. Wang et al. 70 modified the original gene set enrichment analysis algorithm to work with GWAS datasets, using SNP significance and SNP-to-gene mapping instead of gene expression data. In brief, the algorithm calculates an enrichment score for each pathway based on a weighted Kolmogorov-Smirnov statistic (refer to ref. 70 for more details). Pathways that have most of their genes at the top of the ranked list of genes obtain higher enrichment scores. Note that only the largest positive enrichment score was considered as opposed to largest absolute enrichment score (that is, the largest deviation from zero). This modification (recommended by the GenGen authors for GWAS analysis) was performed to include only pathways that are significantly affected between cases and controls and ignore those with significant negative enrichment scores (this may happen if a pathway is significantly less altered than expected by chance). Only pathways containing more than 10 genes with at least one of these genes with P < 5 × 10 −8 were retained as higher confidence for subsequent analysis. These pathways, together with the genes reaching the significance threshold, are listed in Supplementary Table 22 .
The pathway analysis assigns an enrichment score for each pathway. These values were normalized and P values for each pathway were obtained by separately comparing them to null distributions for OncoArray and iCOGS datasets. The null distributions were computed by permuting case/control labels 1,000 times (keeping the number of cases and controls the same in each iteration) and recomputing all enrichment statistics. FDR values were computed using the statistics from the null distributions and all pathways with FDR < 0.05 in either OncoArray or iCOGS distributions were considered further. Pathway findings were further considered if they contained more than one significant gene and if they could be confirmed to be involved in breast cancer as reported in at least one of five published large-scale breast cancer GWAS [71] [72] [73] [74] [75] or reported elsewhere in the literature. Furthermore, themes that were weakly associated with breast cancer (based on a literature search) were only included if they had a FDR < 0.05 and at least four novel genes (that is, was not found among the genes from mapped themes containing pathways known to be involved in breast cancer) (Extended Data Fig. 2) . Pathways related to 'sensory perception of smell' were removed as there is no evidence in the literature for their involvement in breast cancer and because they contain genes close to each other on chromosome 6 that are frequently correlated.
An enrichment map was created using the Enrichment Map version 2.1.0 app 16 in Cytoscape version 3.3 (ref. 76) . Pathway nodes were laid out using a forcedirected layout and nodes with gene set overlap of over 0.55 were connected by n/a Confirmed The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
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Policy information about availability of computer code
Describe the software used to analyze the data in this study.
Analyses were mostly conducted using standard software. These include ShapeIT2, IMPUTE v2, Mach, Minimac, R, and METAL. We used two purpose written software for principal components analysis, pccalc (http://ccge.medschl.cam.ac.uk/ software/pccalc) and for fast logistic logistic regression, mlogit (http:// ccge.medschl.cam.ac.uk/software/mlogit/) For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for providing algorithms and software for publication provides further information on this topic.
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Materials availability
Indicate whether there are restrictions on availability of unique materials or if these materials are only available for distribution by a for-profit company.
No unique materials were used (with the exception of the patient DNA samples). The Oncoarray is available for purchase from Illumina.
Antibodies
Describe the antibodies used and how they were validated for use in the system under study (i.e. assay and species). c. Report whether the cell lines were tested for mycoplasma contamination.
All cell lines tested negative for mycoplasma contamination.
d. If any of the cell lines used are listed in the database of commonly misidentified cell lines maintained by ICLAC, provide a scientific rationale for their use.
No cell lines are on the database of commonly misidentified lines.
